Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer

Clinical Cancer Research

Volumn 5, Issue 12, 1999, Pages 4034-4040

  Beckett, Mary Lou ^a,b,c   Cazares, Lisa H ^a,b,c   Vlahou, Antonia ^a,b,c   Schellhammer, Paul F ^a,b,c   Wright Jr , George L ^a,b,c,d  

^a Dept Microbiol/Molec Cell Biol ^*  (United States)

^b Virginia Prostate Center   (United States)

^c Sentara Cancer Resource Centers   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BLOOD LEVEL; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CARBOXYPEPTIDASES; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES;

EID: 0033400445     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Luderer, A. A., Chen, Y. T., Soriano, T. F., Kramp, W. J., Carlson, G., Cuny, C., Sharp, T., Smith, W., Petteway, J., Brawer, M. K., and Thiel, R. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology, 46: 187-194, 1995.
2. Marley, G. M., Miller, M. C., Kattan, M. W., Zhao, G., Patton, K. P., Vessella, R. L., Wright, G. L., Jr., Schellhammer, P. F., and Veltri, R. W. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. Urology, 48 (Suppl. 6A): 16-22, 1996.
3. Van Cangh, P. J., De Nayer, P., De Vischer, L., Sauvage, P., Tombal, B., Lorge, F., Wese, F. X., and Opsomer, R. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/ml total PSA. Urology, 48 (Suppl. 6A): 67-70, 1996.
4. Reiter, W., Stieber, P., Schmeller, N., Nagel, D., Schambeck, C., and Fateh-Moghadam, A. Is free prostate-specific antigen helpful in the differential diagnosis of benign hyperplasia and cancer of the prostate? Tumor Biol., 18: 80-87, 1997.
5. Abrahamsson, P. A., Lilja, H., and Oesterling, J. E. Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Urol. Clin. N. Am., 24: 353-365, 1997.
6. Mione, R., Barioli, P., Barichello, M., Zattoni, F., Prayer-Galetti, T., Plebani, M., Aimo, G., Terrone, C., Manferrari, F., Maddeddu, G., Caberlotto, L., Fandella, A., Pianon, C., Vianello, L., and Gion, M. Prostate cancer probability after total PSA and percent free PSA determination. Int. J. Biol. Markers. 13: 77-86, 1998.
7. Gion, M., Mione. R., Barioli, P., Barichello, M., Zattoni, F., Prayer-Galetti, T., Plebani, M., Aimo, G., Terrone, C., Manferrari, F., Madeddu. G., Caberlotto, L., Fandella, A., Pianon, C., and Vianello, L. Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions. Clin. Chem., 44: 2462-2470, 1998.
8. Horoszewciz, J. S., Kawinski, E., and Murphy, G. P. Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostate cancer patients. Anticancer Res., 7: 927-936, 1987.
9. Wright, G. L., Jr., Haley, C., Beckett, M. L., and Schellhammer, P. F. Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues. Urol. Oncol., 1: 18-28, 1995.
10. Wright, G. L., Jr., Grob, B. M., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J. K., Konchuba, A., Schellhammer, P. F., and Moriarty, R. Up-regulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology, 48: 326-334, 1996.
11. Elgama, A. A., Troychak, M. J., and Murphy, G. P. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate, 37: 261-269, 1998.
12. Rochon, Y. P., Horoszewicz, J. S., Boynton, A. L., Holmes, E. H., Barren, R. J., III, Erickson, S. J., Kenny, G. M., and Murohy, G. P. Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients. Prostate, 25: 219-223, 1994.
13. Murphy, G., Ragde, H., Kenny, G., Barren, R., III, Erickson, S., Tjoa, B., Boynton, A., Holmes, E., Gilbaugh, J., and Douglas, T. Comparison of prostate specific membrane antigen and prostate specific antigen levels in prostate cancer patients. Anticancer Res., 15: 1473-1480, 1995.
14. Murphy, G. P., Barren, R. J., Erickson, S. J., Bowes, V. A., Wolfert, R. L., Bartsch, G., Klocker, H., Pointer, J., Reissigi, A., McLeod, D. G., Douglas, T., Morgan, T., Kenny, G. M., Ragde, H., Boynton, A. L., and Holmes, E. H. Evaluation and comparison of two new prostate carcinoma markers. Cancer (Phila.), 78: 809-818, 1996.
15. Troyer, J. K., Feng, Q., Beckett, M. L., and Wright, G. L., Jr. Biochemical characterization and mapping of the 7E11 C5.3 epitope of the prostate-specific membrane antigen. Urol. Oncol., 1: 29-37, 1995.
16. Oesterling, J. E., Jacobsen, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A., and Lieber, M. M. Serum prostate-specific antigen in a community-based population of healthy men. J. Am. Med. Assoc., 270: 860-864, 1993.
17. Davis, J. W., McCammon, K. A., Kolm, P., Lynch, D. F., and Schellhammer, P. F. Prostate cancer screening at Eastern Virginia Medical School: age-adjusted reference ranges in African Americans versus Caucasians. J. Urol, 161: 291, 1999.
18. Uria, J. A., Velasco, G., Santamaria, I., Ferrando, A., and Lopez-Otin, C. Prostate-specific membrane antigen in breast carcinoma. Lancet, 349: 1601, 1997.
19. Liu, H., Moy, P., Xia, Y., Kim, S., Xia, Y., Rajasekaran, A., Navarro, V., Knudsen, B.. and Bander, N. H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res., 57: 3629-3634, 1997.
20. Murphy, G. P., Greene, T. G., Tino, W. T., Boynton, A. L., and Holmes, E. H. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J. Urol., 160: 2396-2401, 1998.